A patient is in status asthmaticus after several unsuccessful bronchodilator treatments. Which medication could be helpful?

In the context of a patient experiencing status asthmaticus, the primary goal is to alleviate bronchospasm and improve airflow. Isoproterenol is a non-selective beta-adrenergic agonist that acts on beta-1 and beta-2 receptors, leading to bronchodilation. It is particularly effective in providing rapid relief of bronchospasm, which can be crucial during a severe asthma attack when conventional bronchodilator treatments have failed.

Isoproterenol can quickly relax the smooth muscles of the airway, making it beneficial for patients in acute respiratory distress due to asthma. Its rapid onset of action allows for immediate therapeutic effects, which is critical in managing life-threatening situations like status asthmaticus.

In contrast, the other options do not serve this purpose effectively. Nitroglycerin is primarily a vasodilator and is not indicated for asthma treatment. Keflex is an antibiotic that would not address the acute bronchospasm. Beclovent, a corticosteroid, is more useful for long-term management and inflammation reduction but does not provide immediate bronchodilation needed in acute situations. Therefore, isoproterenol stands out as the appropriate choice for rapidly managing status asthmaticus.